非小细胞肺癌EGFR基因突变治疗方案及医保政策回顾  

Therapeutic Schedule of EGFR Mutation in Non-Small Cell Lung Cancer and Review of Health Insurance Policy

作　　者：高婧 王睿[1] 申越 尹楠 王文杰 曹荣月[1] 

机构地区：[1]中国药科大学,江苏 南京

出　　处：《世界肿瘤研究》2022年第3期174-183,共10页World Journal of Cancer Research

摘　　要：表皮细胞生长因子受体(Epidermal Growth Factor Receptor, EGFR)基因突变是非小细胞肺癌患者(NSCLC)的主要突变之一,该突变的发现推动了小分子靶向药物研究的进展,促使NSCLC患者治疗方法多样化。临床通常采用外科手术切除治疗、放射治疗、化学治疗等传统治疗方案并配合使用分子靶向药物的联合治疗,增加了患者生存获益。本文综述EGFR基因突变的NSCLC患者靶向药物治疗以及部分地区医保政策,旨在为进一步治疗提供参考。The gene mutation of epidermal growth factor receptor (EGFR), which is one of the most vital mutations in patients with non-small cell lung cancer (NSCLC). The discovery of this mutation promotes the research progress of small molecule targeting drugs and the diversification of treatment methods. The therapy has increased the survival benefit of patients, especially those with invasivetumors, which is combinated with surgical resection, radiotherapy, chemotherapy and other traditional therapies combined with molecularly targeted drugs. This article reviews EGFR gene mutations in NSCLC patients targeted drug therapy and some regional health care policy, in order to provide a reference for further treatment.

关 键 词：非小细胞肺癌 表皮细胞生长因子受体 靶向药物 基因突变 临床药物治疗学 

分 类 号：R734.2[医药卫生—肿瘤]